$LENZ Therapeutics: $45 Million Quarterly SG&A Spend and a Surprisingly Small Digital Footprint

LENZ Therapeutics entered 2026 as one of the more interesting ophthalmology launches in the public markets.

The company has:

\- an FDA-approved product (VIZZ),

\- a massive addressable market,

\- a 117-person commercial field force,

\- and quarterly SG&A expenses approaching $45 million.

At the same time, Q1 2026 revenue was only approximately $1.9 million.

For early commercial biotech companies, heavy launch spending is not unusual. What is unusual, however, is the apparent disconnect between the scale of spending and the company’s publicly visible consumer engagement footprint.

\## The Digital Presence Problem

VIZZ is not an ultra-rare orphan drug.

It targets presbyopia — a condition affecting tens of millions of Americans, particularly consumers in the 45–60 demographic. This is one of the most commercially accessible healthcare audiences in the United States and one of the most active demographics on Facebook and YouTube.

Yet publicly visible engagement metrics remain surprisingly small.

\### Facebook (VIZZ)

\- \~710 followers

For a consumer-oriented ophthalmology product targeting a massive age demographic, this level of reach appears extremely limited relative to the scale of commercialization spending.

\### YouTube (VIZZ)

\- \~218 subscribers

\- 6 uploaded videos

\- most videos posted \~9 months ago

\- engagement ranging from roughly \~200 to \~1,200 views

For comparison, many niche healthcare creators and independent optometrists routinely generate significantly larger organic engagement without institutional budgets.

\### X / Twitter (LENZ)

\- official account inactive since January 20, 2022

This is perhaps the most striking datapoint.

The company transitioned through IPO, FDA approval, and commercial launch phases while its primary public communication channel effectively remained dormant.

\### Online Community Presence

There also appears to be limited visible effort toward:

\- Reddit engagement,

\- patient education communities,

\- consumer ambassador programs,

\- or broader social discussion ecosystems around presbyopia treatment.

\## Where Is The $45 Million Going?

This is the central question investors increasingly appear to be asking.

A quarterly SG&A run rate approaching $45 million translates to roughly:

\- \~$15 million per month

\- or approximately \~$500,000 per day

The company clearly invested heavily in:

\- sales infrastructure,

\- physician outreach,

\- commercialization staffing,

\- logistics,

\- and launch preparation.

However, the visible consumer-facing footprint does not currently reflect the scale typically associated with a modern direct-to-consumer healthcare rollout.

The current strategy appears heavily weighted toward:

\- traditional pharma commercialization,

\- physician-driven adoption,

\- and field sales execution.

That approach may ultimately work.

But in 2026, the absence of a meaningful digital ecosystem around a mass-market vision product raises legitimate questions about capital efficiency and launch scalability.

\## The Bull Case Still Exists

Importantly, weak social engagement alone does not mean VIZZ will fail commercially.

In fact:

\- physician-driven ophthalmology launches can scale slowly at first,

\- prescription adoption often precedes online popularity,

\- and repeat usage metrics matter far more than follower counts.

There are also early anecdotal indications that many patients who try the product report meaningful benefit after an initial adjustment period.

If refill rates and physician retention prove strong, current digital metrics may ultimately prove irrelevant.

\## But The Market Is Clearly Looking For Proof

The market reaction following recent earnings suggests investors are no longer rewarding the story alone.

The key debate has shifted from:

“Can LENZ launch VIZZ?”

to:

“Can LENZ scale VIZZ efficiently?”

And right now, the public-facing commercial signals appear surprisingly small relative to the size of the spending base.

The next several quarters will likely determine whether the company’s physician-first strategy was disciplined long-term execution — or an expensive underinvestment in modern consumer engagement.